Managing catastrophic medical claims -prescription drug trends

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<rdf:Description>
<dc:creator>Troutman, Mark</dc:creator>
<dc:creator>Jackson, Larry P.</dc:creator>
<dc:date>2019-01-07</dc:date>
<dc:description xml:lang="es">Sumario: The major impact trend on catastrophic medical claims is specialty pharmacy developments in biosimilars, orphan drugs, and breakthrough therapies. This increasing pipeline of new specialty drugs and targeted therapies results from several market trends. Pharmaceutical manufacturers continue their direct-to-consumer advertising to increase consumer awareness. Increased utilization naturally occurs due to the aging population and trend toward outpatient health care, as well as new and more aggressive drug treatment plans. This situation creates a pushpull conflict between supplier and payer as suppliers push for solutions at highest cost to increase margin and payers push for solutions and lowest cost to increase bottom line.</dc:description>
<dc:identifier>https://documentacion.fundacionmapfre.org/documentacion/publico/es/bib/168652.do</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights xml:lang="es">InC - http://rightsstatements.org/vocab/InC/1.0/</dc:rights>
<dc:subject xml:lang="es">Reclamaciones</dc:subject>
<dc:subject xml:lang="es">Industria farmacéutica</dc:subject>
<dc:type xml:lang="es">Artículos y capítulos</dc:type>
<dc:title xml:lang="es">Managing catastrophic medical claims -prescription drug trends</dc:title>
<dc:format xml:lang="es">5 p. </dc:format>
<dc:relation xml:lang="es">En: Contingencies : American Academy of Actuaries. - Washington : American Academy of Actuaries, 2019-2024. - 07/01/2019 Año 2019 - January-February , p. 38-42</dc:relation>
</rdf:Description>
</rdf:RDF>